Showing results (31-40 of 41) with videos related to
Sort By:
Pageof 5
Clinical Biochemistry|December 27, 2016
The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian studyFlorence Van Obbergh, Laurent Knoops, Timothy Devos, et al.Blood|March 2, 2012
Thrombopoietin receptor down-modulation by JAK2 V617F: restoration of receptor levels by inhibitors of pathologic JAK2 signaling and of proteasomesChristian Pecquet, Carmen C Diaconu, Judith Staerk, et al.Blood|January 21, 2014
Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohortsFrancesco Passamonti, Margherita Maffioli, Francisco Cervantes, et al.Blood|November 1, 2013
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisFrancisco Cervantes, Alessandro M Vannucchi, Jean-Jacques Kiladjian, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2007
Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphomaAnnuska M Glas, Laurent Knoops, Leonie Delahaye, et al.British Journal of Haematology|May 16, 2013
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapyClaire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, et al.British Journal of Haematology|July 16, 2013
Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groupsJean-Christophe Ianotto, Françoise Boyer-Perrard, Emmanuel Gyan, et al.Haematologica|January 21, 2018
A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphomaEric Van Den Neste, Marc André, Thomas Gastinne, et al.Haematologica|December 9, 2017
Benefits and pitfalls of pegylated interferon-α2a therapy in patients with myeloproliferative neoplasm-associated myelofibrosis: a French Intergroup of Myeloproliferative neoplasms (FIM) studyJean-Christophe Ianotto, Aurélie Chauveau, Françoise Boyer-Perrard, et al.The Journal of Experimental Medicine|March 26, 2008
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemiaElisabetta Flex, Valentina Petrangeli, Lorenzo Stella, et al.Pageof 5